1-11114363-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_004958.4(MTOR):c.7255G>A(p.Glu2419Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_004958.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1Other:1
- -
MTOR: PS2, PM2, PS4:Moderate, PP2, PP3 -
Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes Pathogenic:1
An MTOR c.7255G>A (p.Glu2419Lys) variant was identified at an allelic fraction consistent with somatic origin. This variant has been reported in several individuals with MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities (Carmignac V et al., PMID: 33833411; Vabres P et al., PMID: 26269266, Hadouiri N et al., PMID: 32805448; Bourgon N et al., PMID: 34170046) and has also been reported in multiple cancer cases in the cancer database COSMIC (COSMIC ID: COSV63869451). It is absent from the general population (gnomAD database v4.1.0), indicating it is not a common variant. This variant has been reported in the ClinVar database as a pathogenic variant by three submitters (ClinVar ID: 156709). The MTOR c.7255G>A (p.Glu2419Lys) variant resides within the kinase domain of MTOR that is defined as a critical functional domain (Carmignac V et al., PMID: 33833411; Mroske C et al., PMID: 26542245). Computational predictors indicate that the variant is damaging, evidence that correlates with impact to MTOR function. In support of this prediction, in vitro functional studies showed that the p.Glu2419Lys variant increased kinase activity, leading to elevated levels of phosphorylated AKT and p70S6K, indicating that this variant impacts protein function (Carmignac V et al., PMID: 33833411; Mroske C et al., PMID: 26542245; Yang H et al., PMID: 23636326). The MTOR gene is defined by the ClinGen's Brain Malformations expert panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (Lai A et al., PMID: 35997716). Based on available information and an internally developed protocol informed by the ACMG/AMP guidelines for variant interpretation and gene-specific practices from the ClinGen Criteria Specification Registry (Leon-Quintero FZ et al., PMID: 39434542), the MTOR c.7255G>A (p.Glu2419Lys) variant is classified as pathogenic. -
Inborn genetic diseases Pathogenic:1
The c.7255G>A (p.E2419K) alteration is located in exon 53 (coding exon 52) of the MTOR gene. This alteration results from a G to A substitution at nucleotide position 7255, causing the glutamic acid (E) at amino acid position 2419 to be replaced by a lysine (K). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been determined to be the result of a de novo mutation or germline mosaicism in two individuals and heterozygous in two individuals with infantile onset seizures, developmental delay, hemimegalencephaly, ventriculomegaly, linear hypomelanosis, left overgrowth, and/or dysmorphic facial features (Garcia, 2020; Carmignac, 2021; Fu, 2022) This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). Functional studies suggest a gain of function effect; however, additional evidence is needed to confirm this finding (Urano, 2007; Wagle, 2014). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. -
Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome Pathogenic:1
- -
CEBALID syndrome Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at